Sarah Cannon Research Institute (SCRI) and AstraZeneca will collaborate to develop new AstraZeneca oncology compounds. The companies will work on molecular profiling to classify tissue based on genetic profiles for the purpose of treating cancers and predicting response to therapy.

The companies will identify potential patients for clinical trials and explore biomarkers that predict response to specific treatments. In addition, SCRI’s enhanced relationship with AstraZeneca will provide clinical program development leadership, medical expertise and oversight and operational CRO trial management for early phase clinical development of multiple oncology compounds.

“Building upon this collaboration with SCRI allows us to continue honing our capabilities to deliver quality research in a timely and cost-effective manner,” said Andrew Hughes, vice president of early clinical development for AstraZeneca. “Through this program design, we can implement clinical trials with greater access to a network of cancer patients for enrollment.”